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Objectives: Chronic pressure overload cardiac hypertrophy produces ventricular
dysfunction. There is evidence that clenbuterol, a β2-adrenoceptor agonist, produces
cardiac hypertrophy with preserved function in rodents. We sought to determine the
cardiac hypertrophic effects of clenbuterol on the thin-walled ventricles of large ani-
mals undergoing chronic pressure overload by means of pulmonary artery banding.
Methods: Right ventricular pressure-volume loops were obtained in open-chest
sheep before and after 61⁄2 weeks of pulmonary artery banding by using micro-
manometer conductance catheters. Animals were randomly assigned to treatment
with either saline solution (n = 7) or clenbuterol (n = 8). Treatment was started
immediately after pulmonary artery banding.
Results: Acute pulmonary artery banding increased the right ventricular systolic
pressure equally in both groups (saline group, 23.9 ± 3.3 to 48.1 ± 9.7 mm Hg; clen-
buterol group, 24.3 ± 2.8 to 48.6 ± 10.7 mm Hg [mean ± standard deviation]). Six
weeks of treatment produced no significant differences in the body weight, heart
weight, heart/body weight ratio, right ventricular wall thickness, heart rate, and
stroke volume between the groups. However, the slope of the end-systolic pressure-
volume relation and the slope of the first derivative of the right ventricular devel-
oped pressure/end-diastolic volume relation were significantly increased when com-
pared with baseline values in clenbuterol-treated animals but not in saline-treated
animals.
Conclusion: Clenbuterol treatment during pulmonary artery banding improves sys-
tolic function of the chronically pressure-overloaded right ventricle. This has impor-
tant implications for the use of pharmacologic agents in modulating cardiac adapta-
tion.
The 2-stage arterial switch operation (ASO) was first described in19771 and is now rarely used, except in patients with transposition ofthe great arteries (TGA) and intact ventricular septum presentingafter the neonatal period2 and in situations in which the right ventri-cle has failed after a previous atrial switch operation.3,4 Recentrevival of interest in this technique has stemmed from the published
long-term results of inflow correction operations (Senning and Mustard operations)
for TGA, which showed progressive right ventricular dysfunction over time,5,6 sug-
gesting that a significant proportion of these patients will require surgical interven-
tion, probably in the form of the 2-stage ASO. The first stage of the 2-stage ASO
involves pulmonary artery banding (PAB) to create pressure overload cardiac hyper-
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trophy in the thin-walled, low-pressure morphologically left
ventricle. However, cardiac hypertrophy induced by pres-
sure overload has been known to be initially compensatory
to normalize wall stress but eventually leads to ventricular
dysfunction and heart failure, as illustrated by the increased
morbidity and mortality in hypertensive heart disease in the
presence of cardiac hypertrophy.7 For the same reason, dete-
rioration of left ventricular function has been reported, par-
ticularly in older children at medium-term follow-up after
the 2-stage ASO.8,9
Hence, the induction of physiologic cardiac hypertrophy
without adverse effect, like that achieved with exercise train-
ing,10 is desirable in cardiac operations. Clenbuterol, a selec-
tive β2-adrenergic receptor agonist, has been shown to induce
cardiac hypertrophy in rats with molecular and functional
parameters consistent with those of physiologic cardiac hyper-
trophy.11,12 In addition, attenuation of the pathologic molecu-
lar and functional characteristics of pressure-overload left ven-
tricular hypertrophy induced by clenbuterol has also been
reported.13 These reports on clenbuterol have been supported
by communications from various groups reporting the benefi-
cial functional effects of β2-adrenergic receptor overexpres-
sion in mice hearts.14-16 The study by Liggett and associates14
in particular showed that the positive effects of β2-adrenergic
receptor overexpression on cardiac function was present at 1
year as long as a certain threshold for spontaneous receptor
activation was not exceeded.
The effects of clenbuterol on thin-walled, low-pressure
ventricles, such as those seen in the morphologically left
ventricle in TGA, have not been studied. There is also a lack
of information on the cardiac effects of clenbuterol in large
mammalian species. Small animal hearts are different from
those of large animals both functionally and at the molecu-
lar level. For example, in small animals the α cardiac
myosin heavy chain constitutes close to 90% of total cardiac
myosin heavy chain, whereas in human subjects it consti-
tutes only 10%.
The aim of the current study is to test the hypothesis that
clenbuterol, when given at the time of induction of pressure-
overload cardiac hypertrophy in the right ventricles of sheep
by means of PAB, improves right ventricular systolic func-
tion. Banding of the pulmonary artery will simulate the
hemodynamic condition in the first stage of the 2-stage
ASO, during which banding is performed to induce hyper-
trophy in the thin-walled, low-pressure morphologically left
ventricle.
Methods
Fifteen Dorset Down sheep with a body weight of 23.53 ± 5.30 kg
(mean ± SD) were cared for in accordance with the guidelines laid
down by the Home Office of Great Britain and Northern Ireland
(1986). All were given food and water ad libitum and underwent 1
to 2 weeks of settlement before any procedures were performed.
Surgical Preparation
Premedication with ketamine (100-150 mg) and diazepam (10 mg)
were administered intramuscularly. General anesthesia was
induced with inhalation of halothane and maintained by means of
intubation and ventilation with a mixture of oxygen (49.5%),
nitrous oxide (49.5%), and halothane (1%) with a standard venti-
lator (Harvard Apparatus, Inc, Holliston, Mass). Muscle relaxants
were omitted. A 6F thermodilution catheter was introduced into
the right side of the heart through the left jugular vein for central
venous pressure, pulmonary artery pressure, and cardiac output
measurements. The left carotid artery was cannulated for systemic
arterial pressure monitoring. The ruminant stomach was decom-
pressed with a 12-bore orogastric tube. Arterial oxygen saturation
was monitored with a pulse oximeter and maintained at 90% to
100%. Ringer’s lactate solution was infused into a peripheral vein
throughout the study at 1 to 2 mL · kg–1 · h–1 and occasionally sup-
plemented with sodium bicarbonate to maintain a near-normal
base deficit. PAB was performed through a left thoracotomy inci-
sion, and the pericardium was opened fully. Inflow reduction to the
heart during generation of the end-systolic pressure-volume rela-
tion was achieved by lifting a nylon tape passed around the inferi-
or vena cava for no more than 8 seconds. Left atrial pressure was
measured directly by using a fluid-filled manometer with a 14-
gauge hypodermic needle. A 5F, 12-electrode (5 mm of interelec-
trode distance) combined micromanometer conductance catheter
(Millar Instruments, Inc, Houston, Tex) was inserted into the right
ventricle through a purse-string suture at the top of the right ven-
tricular outflow tract, just below the pulmonary valve. The con-
ductance catheter was then connected to a signal conditioner
processor (Leycom Sigma5-DF, CD Leycom, Zoetermeer, The
Netherlands) to convert instantaneous conductance measurements
into volume. All analogue signals were digitized with 12-bit accu-
racy on an IBM-compatible personal computer at a sampling rate
of 200 Hz and saved on a hard disk for subsequent analysis.
The application, validation, and calibration of the conductance
technique for measuring ventricular volume was described else-
where.17 Although originally designed for use in the left ventricle,
the feasibility of conductance catheter measurements in the right
ventricle has recently been demonstrated.18-20
Figure 1. Effects of PAB on right ventricular systolic pressure.
There is no difference in the right ventricular systolic pressure at
the 3 time points recorded. However, the pressures at the chronic
stage are lower than those recorded at the acute stage in both
groups. *P < .001 versus baseline; **P < .05 versus acute stage.
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Study Protocol
Once the conductance catheter was in the optimal position, a 15-
minute period was allowed for the animal to reach hemodynamic
stability. Right ventricular pressure-volume loops during steady
state, preload reduction, cardiac output measurements (with the
thermodilution technique), and hypertonic saline injection (for
measurement of parallel conductance) were then obtained at base-
line before PAB. All measurements were taken at end-expiration
with the ventilator turned off. The pulmonary artery band was
adjusted to maximum tolerable tightness by not allowing the sys-
tolic arterial blood pressure to fall below 60 mm Hg at any time
during the experiment. Further tightening of the band resulted in
severe bradycardia and rapid decline in systemic arterial blood
pressure, which normalized when the band was released immedi-
ately. All catheters were then removed, and the chest was closed.
After successful PAB, the sheep were randomly assigned to 2
groups: the saline treatment group (n = 7) and the clenbuterol treat-
ment group (n = 8).
On the first postoperative day, the sheep were treated with
either 2 mL of saline solution or 0.5 mg/kg clenbuterol
(Boehringer-Ingelheim, Berkshire, United Kingdom), adminis-
tered by means of once daily subcutaneous injection, for a total
duration of 6 weeks. Injections were stopped 3 days before the
restudy as a wash-out period to avoid any direct inotropic effect of
clenbuterol on the myocardium, thus allowing us to assess the true
intrinsic myocardial pump function.
Restudy was performed by using exactly the same technique
through a median sternotomy. Animals were put to death at the
end of the experiment by means of exsanguination while the
heart was harvested. After the PAB had been identified, the great
vessels were trimmed away, and the hearts were weighed and
examined for right ventricular and left ventricular wall thickness
by using a pair of vernier calipers (measurements taken at the
base of the anterior papillary muscle and middle of the septum).
Wall thickness measurements were taken 3 times, and the aver-
age was calculated. The right ventricular free wall was not
weighed separately.
Data and Statistical Analysis
Analysis of the pressure-volume loops was achieved by using a
customized software package. Three load-independent indices of
systolic function were used in this study to quantify right ventric-
ular performance: slope of the end-systolic pressure-volume rela-
tion (Ees); slope of the first derivative of the right ventricular pres-
sure-end diastolic volume relation (dp/dtmax-Ved), and the preload
recruitable stroke work relation (PRSW). Within-group analysis of
all parameters was performed by using the paired Student t test. All
between-group analyses were performed by using the unpaired
Student t test. All results shown in the text and tables are expressed
as means ± SD.
Results
Hemodynamic Data
Acute right ventricular peak systolic pressure after PAB
(saline group, 48.1 ± 9.7 mm Hg; clenbuterol group, 48.6 ±
10.7 mm Hg; P = .93) and at the 61⁄2-week chronic stage
(saline group, 39.3 ± 3.9 mm Hg; clenbuterol group, 36.5 ±
3.7 mm Hg; P = .18) were not different between the 2 groups
(Figure 1). The response of the various hemodynamic vari-
ables to PAB is presented in Table 1. PAB produced no sig-
nificant changes to the heart rate and left atrial pressure in
both groups, suggesting that the bands were not excessively
tight, nor was there any difference seen in any of the param-
eters between the 2 groups. The right ventricular systolic
pressure and right ventricular/left ventricular systolic pres-
sure ratio in both groups rose significantly after PAB when
compared with baseline values. At the chronic stage, both
variables were significantly reduced when compared with
the corresponding values at the acute stage but remained sig-
nificantly elevated compared with baseline values.
Weight and Wall Thickness
Sheep in both groups continued to grow after PAB.
Although the saline-treated animals started with a slightly
lower mean baseline body weight, there was no significant
difference between the 2 groups (Table 2). Six weeks of
clenbuterol treatment produced no significant difference in
the mean body weight increase, heart weight, heart/body
weight ratio, and interventricular septum thickness between
TABLE 1. General hemodynamics 
Baseline Acute Chronic
Saline Clenbuterol Saline Clenbuterol Saline Clenbuterol
Heart rate (beats/min) 114 ± 16 116 ± 23 127 ± 19 133 ± 20 106 ± 28 121 ± 18
Systolic arterial blood pressure (mm Hg) 78 ± 9 82 ± 11 72 ± 8 76 ± 11 75 ± 8 81 ± 13
RV/LV systolic pressure ratio 0.31 ± 0.03 0.30 ± 0.03 0.66 ± 0.10* 0.64 ± 0.08* 0.53 ± 0.07*† 0.46 ± 0.11*†
RV systolic pressure (mm Hg) 24 ± 3 24 ± 3 48 ± 10* 49 ± 11* 39 ± 4*† 37 ± 4*†
Central venous pressure (mm Hg) 8.6 ± 2.8 8.1 ± 1.1 12.9 ± 2.3* 12.4 ± 1.9* 11.1 ± 2.7* 12.3 ± 3.8*
Left atrial pressure (mm Hg) 4.4 ± 2.1 4.4 ± 0.9 3.9 ± 1.6 3.6 ± 0.9 4.4 ± 1.0 3.8 ± 1.0
No significant differences between the saline and clenbuterol groups were found at any stage (ie, baseline, acute, or chronic).
RV, Right ventricle; LV, left ventricle.
*P < .05 versus baseline.
†P < .05 versus acute stage.
Cardiopulmonary Support and Physiology Hon et al
770 The Journal of Thoracic and Cardiovascular Surgery • October 2001
ED
ITO
RIA
L
CH
D
CPS
A
CD
ET
CSP
TX
the 2 groups of animals (Table 2). There was, however, an
incremental trend in the right ventricular wall thickness, the
right ventricular/left ventricular wall thickness ratio (saline
group, 0.67 ± 0.08; clenbuterol group, 0.76 ± 0.10; P = .07),
and the right ventricular wall thickness/end-diastolic vol-
ume ratio in the clenbuterol-treated animals, although these
parameters did not reach statistical significance.
Volumetric Data
Conductance-derived volumetric data presented in Table 3
showed that mean end-diastolic and end-systolic volumes
were slightly (but not significantly) larger in the clen-
buterol-treated animals, possibly related to their slightly
higher body weight. There was a greater tendency for both
the end-diastolic volumes (saline group, 51% increase; clen-
buterol group, 30% increase) and the end-systolic volumes
(saline group, 102% increase; clenbuterol group, 58%
increase) to increase after banding in saline-treated animals
compared with that seen in clenbuterol-treated animals,
although this did not reach statistical significance. This ten-
dency was further exaggerated after indexing the volumes to
body weight (indexed end-diastolic volume: saline group,
35% increase; clenbuterol group, 8% increase; indexed end-
systolic volume: saline group, 79% increase; clenbuterol
group, 35% increase). Correspondingly, no significant
change to the right ventricular stroke volumes and right ven-
tricular output were seen in either group.
Right Ventricular Systolic Function
Data for right ventricular systolic function are shown in
Figure 2, A and B, and Table 4. The Ees and the dp/dtmax-
Ved were increased significantly when compared with base-
line in animals that were treated with clenbuterol but not in
those that were treated with saline solution (Ees: saline
group, 2.38 ± 0.42 to 3.40 ± 0.69 mm Hg/mL, P = .47; clen-
buterol group, 1.82 ± 0.51 to 5.68 ± 0.90 mm Hg/mL, P =
.01; dp/dtmax-Ved: saline group, 11.18 ± 9.25 to 12.11 ±
3.71 mm Hg · mL–1 · s–1, P = .74; clenbuterol group, 8.82 ±
4.38 to 20.0 ± 7.74 mm Hg · mL–1 · s–1, P = .01). This is evi-
dence for improvement in right ventricular systolic function
after clenbuterol treatment. Analysis of the third load-inde-
pendent index PRSW showed that clenbuterol-treated ani-
mals demonstrated a 32% greater increase compared with
that seen in the saline group, although this increase did not
reach statistical significance.
Discussion
The present study shows that the β2-adrenergic receptor
agonist clenbuterol improves the systolic function of the
thin-walled, low-pressure right ventricle of sheep after 61⁄2
weeks of PAB. The highly significant improvement in func-
tion was reflected by a 212% increase in Ees in the clen-
buterol group compared with a 43% increase in the saline
group. This is illustrated in Figure 3. Similar evidence came
from dp/dtmax-Ved, in which there was a 127% increase in
TABLE 2.  Characteristics of saline- and clenbuterol-treated sheep
Saline Clenbuterol
Mean baseline body weight (kg) 22.21 ± 6.15 24.69 ± 4.53
Mean body weight increase (kg) 6.07 ± 2.59 6.44 ± 3.58
Heart weight (g) 204.2 ± 18.8 212.0 ± 22.2
Heart/body weight ratio (×10–3) 7.59 ± 1.56 6.98 ± 1.07
RV wall thickness (mm) 7.4 ± 0.8 8.1 ± 0.9
RV/LV wall thickness ratio 0.67 ± 0.08 0.76 ± 0.10
Interventricular septum thickness (mm) 9.4 ± 1.4 9.4 ± 1.2
RV wall thickness/Ved ratio (mm/mL) 0.23 ± 0.08 0.29 ± 0.19
P values are not significant. RV, Right ventricle; LV, left ventricle; Ved, right ventricular end-diastolic volume.
TABLE 3.  RV volumetric data
Baseline Chronic
Saline Clenbuterol Saline Clenbuterol
RV end-diastolic volume (mL) 22.4 ± 8.2 31.4 ± 14.7 33.9 ± 8.9 40.8 ± 29.1
RV end-systolic volume (mL) 10.9 ± 3.9 17.8 ± 11.1 22.0 ± 9.3 28.1 ± 26.4
RV indexed end-diastolic volume (mL/kg) 0.97 ± 0.18 1.26 ± 0.49 1.31 ± 0.54 1.36 ± 0.98
RV indexed end-systolic volume (mL/kg) 0.47 ± 0.10 0.70 ± 0.40 0.85 ± 0.42 0.95 ± 0.88
RV stroke volume (mL) 12.0 ± 5.0 15.1 ± 5.0 13.8 ± 2.7 13.5 ± 4.5
RV ventricular output (mL/min) 1303.2 ± 450.3 1844.5 ± 580.0 1604.0 ± 443.6 1843.9 ± 685.5
RV ejection fraction (%) 53.1 ± 9.3 52.2 ± 13.8 42.0 ± 8.3 42.4 ± 22.9
P values are not significant. RV, Right ventricle; LV, left ventricle.
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the clenbuterol group compared with the corresponding
value of 8% in the saline group. The technique used in the
current study has been known to be a relatively load-
independent way of assessing ventricular function.
However, the usefulness of the Ees to characterize ventricular
contractility has been put into doubt by some investigators in
recent years because of evidence of afterload dependen-
cy.21,22 Our study results could not have been affected by
this dependence on afterload because the increase in after-
load in both groups both acutely and after 61⁄2 weeks of
banding (as reflected by the right ventricular peak systolic
pressure at both time points) were not significantly different
from each other. Any afterload dependency would have
affected both groups equally. De Vroomen and colleagues20
reported an increase in Ees of more than 50% shortly after
acute right ventricular pressure overload. In the current
study the acute increase in right ventricular afterload is
greater than that reported by de Vroomen and colleagues.
However, the Ees in the saline-treated animals is less than
that reported by these authors, suggesting that right ventric-
ular function may have deteriorated since banding took
place. It can be concluded that the modest 43% increase in
Ees in the saline group is the result of a combination of
afterload-induced improvement in contractility (homeomet-
ric autoregulation), ventricular dysfunction, and other com-
mon features present in both groups. Any further increase in
Ees beyond this point, as seen in the clenbuterol group, must
be due to the effect of clenbuterol. As a result of improved
contractility, clenbuterol-treated animals were relying more
on their intrinsic pump property and less on the Frank-
Starling mechanism to overcome the increased afterload
resistance. In contrast, in the saline-treated animals stroke
volumes and ventricular outputs were maintained at the
expense of a greater degree of ventricular dilation. If the
clenbuterol-treated animals were allowed to increase their
preload to the degree seen in the saline-treated animals, the
highly load-dependent parameters, such as stroke volumes
and ventricular outputs, would be significantly increased. In
contrast to Ees and dp/dtmax-Ved, PRSW did not show a sig-
nificant increase in the clenbuterol group, although there
was an incremental trend toward increase. This could be
explained by the less sensitive nature of this index for
detecting changes in systolic contractility among the 3
indices reported here23 because PRSW describes the entire
cardiac cycle rather than reflecting pure systolic property.
However, we cannot exclude the possibility that patho-
logic changes may develop if treatment is prolonged beyond
6 weeks nor can we predict the longevity of this improved
function when treatment is discontinued for a longer period
of time than the 3 days in the current study. Nevertheless,
the ability of clenbuterol to augment the systolic function of
the chronically pressure-overloaded thin-walled ventricle is
potentially desirable in various surgical settings.
Pharmacological modulation of hypertrophy may improve
surgical outcome, particularly that of the 2-stage ASO for
the TGA, by reducing the degree of hypertrophy and pres-
sure overload needed and by preserving ventricular func-
tion. The potential use of clenbuterol may be further opti-
mized by starting treatment several weeks before PAB to
counter acute ventricular failure, which is a common reason
for unsuccessful banding in TGA. However, in our study
starting clenbuterol early would not have allowed us to mea-
sure the true baseline contractility because of direct β-
adrenergic stimulation on the heart. In addition, starting
clenbuterol treatment before band placement might have led
to different degrees of band tightness in the 2 groups, hence
making the final assessment of ventricular systolic function
difficult to interpret.
It is generally accepted that chronic stimulation with
sympathomimetic agents has deleterious effects on myo-
cardial function that is associated with poor outcome.24
This concept is further illustrated by the benefits of β-
adrenergic receptor blockade in heart failure.25 However,
Liggett and coworkers,14 and previously Milano and col-
Figure 2. Indices of systolic ventricular function. A, Ees; B, dp/dtmax-Ved. *P = .01 versus baseline; +P < .05 ver-
sus saline treatment.
A B
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leagues,15 have shown in transgenic mice that increased β2-
adrenergic receptor expression and activity is in fact bene-
ficial to ventricular function. Liggett and colleagues14
showed that this is true as long as the level of receptor over-
expression does not exceed that for spontaneous activation,
which in their experiment was between 150 and 350 times
the background β2-adrenergic receptor expression.
Furthermore, they have also demonstrated that the hearts
tolerated enhanced contractile function caused by 60-fold
β2-adrenergic receptor overexpression without detriment
for a period of at least 1 year. Our current results in sheep
are in direct agreement with their findings, suggesting that
not only the beneficial effects of β2-adrenergic receptor
stimulation on ventricular function in mice is reproducible
in the large animal species but also that clenbuterol is able
to modulate an otherwise pathologic hypertrophy process
into one that is more physiologic in nature, as illustrated by
the improved systolic function and the 26.1% greater wall
thickness/end-diastolic volume ratio (Table 2). In the cur-
rent report clenbuterol treatment was initiated on the day
after the initial operation, and function was assessed again
only at the end of the 6-week treatment period. Hence, it is
not possible to know whether this modulation process is
achieved by stimulating physiologic cardiac growth from
the outset or by transforming pathologic cardiac growth
into physiologic growth sometime during the experimental
period. Although in the current study we do not know the
effect of clenbuterol in animals that have not undergone
PAB, previous reports by Petrou,12 Wong,11 and their col-
leagues showed conclusively that clenbuterol can stimulate
left ventricular hypertrophy in the absence of pressure
overload with normal ventricular function and physiologic
molecular phenotype (eg, elevated levels of mRNA to atri-
al natriuretic factor without a concomitant increase in
skeletal α actin and β myosin heavy chain and normal
expression of sarcoplasmic reticulum Ca2+-ATPase2a
(SERCA2a), phospholambin mRNA and collagen in an
otherwise healthy normal rat heart. Furthermore, Wong and
colleagues13 documented the ability of clenbuterol to mod-
ulate the pathologic morphology, molecular markers, and
functional phenotype of the pressure-overloaded hypertro-
phied left ventricles toward normality (eg, improvements in
the sarcoplasmic reticulum Ca2+-ATPase2a mRNA levels
and normal collagen concentrations in clenbuterol-treated
hearts). In the latter study, pressure overload to the left ven-
tricle was achieved by banding of the ascending aorta, and
Wong and colleagues13 observed that clenbuterol produced
a specific form of cardiac hypertrophy with improved ven-
tricular function and normal collagen concentration.
Clenbuterol, however, produced only a modest (and non-
significant) increase in the left ventricular mass index in
excess of that already caused by banding alone (11%). This
is in direct agreement with our current data on ventricular
wall thickness and function. The dose of 0.5 mg/kg used in
this study was based on our previous work,26 although no
formal clinical dose-response trials have been performed.
Recently published skeletal muscle data from work per-
formed on goats suggested that smaller oral doses (450
µg/wk) used for human subjects were equally effective in
enhancing muscle function.27 In our current study it would
seem that 6 weeks of clenbuterol treatment was effective in
producing significant improvement in systolic function.
Hence, tachyphylaxis, even if present, does not seem to
cause any limitation to its use in this context.
Figure 3. Typical example of the pressure-volume loops obtained at baseline and at chronic stage: clenbuterol-
treated animal (A) and saline-treated animal (B). Notice the increase in slope between the 2 time points is more
marked in the clenbuterol-treated animal.
A B
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From the pressure-volume loops presented in Figure 3,
one might suspect the presence of tricuspid regurgitation
after PAB because of the lack of an isovolumic phase during
early systole and ejection of the right ventricle started
before the pulmonary arterial end-diastolic pressure was
reached. This could explain the small but nonsignificant
increase in the right ventricular end-diastolic volume and
the lower right ventricular peak systolic pressure recorded at
restudy compared with that recorded acutely after banding.
The increase in central venous pressure seen in our study
would also be consistent with tricuspid regurgitation.
Despite this, pressure-volume analysis describes global
pump function and is relatively independent of preload,28
which is one of the valuable benefits in pressure-volume
analysis. However, the stroke volume, and hence ventricular
output measured by the conductance catheter, will be over-
estimated by including the volume of blood that is ejected
into the right atrium. Thus, the true forward cardiac output
might have remained unchanged or even decreased in our
experiment. The latter is unlikely because the left atrial
pressure remained unchanged after the banding procedure.
The limitations of our study include the following. First,
we have not, in the present study, examined the morpholog-
ic or molecular markers to validate the physiologic changes.
Second, in the present study we did not quantify the
amount of right ventricular hypertrophy caused by the effect
of banding alone. However, the right ventricular/left ven-
tricular wall thickness ratio for the 2 groups listed in Table
2 suggested that there was a moderate degree of right ven-
tricular hypertrophy produced in our current model.29,30
Third, the left ventricular systolic pressure, as reflected
by the arterial systolic pressure, at all 3 time points was
lower than what would normally be expected in sheep. This
could be due to the anesthetic conditions causing vasodi-
latation. In an attempt not to hemodilute the circulating
blood or to cause excess ventricular distention, no bolus vol-
ume infusion was attempted. This regimen was used for all
animals, and any hemodynamic effect would have affected
both groups of animals equally. However, the changes in
right ventricular pressure in response to PAB could be
underestimated as a result of interventricular interaction.
In conclusion, we have demonstrated that simultaneous
treatment with clenbuterol, a β2-adrenergic receptor agonist,
during 61⁄2 weeks of PAB improves right ventricular systolic
function with no detrimental hemodynamic effects. This has
important implications in various clinical settings, particu-
larly in the training of the left ventricle in operations for cer-
tain types of congenital heart disease. The present study and
other previous reports14,15 challenge the current notion that
any chronic catecholamine stimulation is deleterious to the
heart. On the basis of the fact that most of the toxic effects
of β-adrenergic stimulation appears to be mediated largely
by the β1-adrenergic receptors,31 we speculate that concur-
rent use of β2-adrenergic receptor agonist, such as clen-
buterol, together with a selective β1-adrenergic receptor
blocker could be beneficial in certain clinical settings.
We thank Dr M. Al-Obaidi, Dr G. Carr-White, and Dr H. Khan
for their contributions to the preparation of this manuscript and
Boehringer-Ingleheim, UK, for generously supplying the clen-
buterol used in this study.
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